Intuit vs Sage Therapeutics Which Is More Lucrative?

Intuit Inc. and Sage Therapeutics are both publicly traded companies within the financial technology and biopharmaceutical industries, respectively. Intuit is known for its popular financial software products such as QuickBooks and TurboTax, while Sage Therapeutics focuses on developing innovative treatments for various neurological and neuropsychiatric disorders. Investors interested in these stocks may want to compare factors such as revenue growth, profitability, and competition within their respective industries to make informed investment decisions.

Intuit or Sage Therapeutics?

When comparing Intuit and Sage Therapeutics, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between Intuit and Sage Therapeutics.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. Intuit has a dividend yield of 0.69%, while Sage Therapeutics has a dividend yield of -%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. Intuit reports a 5-year dividend growth of 14.59% year and a payout ratio of 34.90%. On the other hand, Sage Therapeutics reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with Intuit P/E ratio at 65.90 and Sage Therapeutics's P/E ratio at -1.14. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. Intuit P/B ratio is 10.59 while Sage Therapeutics's P/B ratio is 0.70.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, Intuit has seen a 5-year revenue growth of 1.19%, while Sage Therapeutics's is -0.26%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with Intuit's ROE at 16.67% and Sage Therapeutics's ROE at -50.29%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are $682.30 for Intuit and $6.29 for Sage Therapeutics. Over the past year, Intuit's prices ranged from $523.32 to $698.96, with a yearly change of 33.56%. Sage Therapeutics's prices fluctuated between $5.64 and $28.26, with a yearly change of 401.06%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.